[1] Andersson E., Rück C., Lavebratt C., Hedman E., Schalling M., Lindefors N., … Furmark T. (2013). Genetic polymorphisms in monoamine systems and outcome of cognitive behavior therapy for social anxiety disorder.PloS one, 8(11), e79015. doi: 10.1371/journal.pone.0079015
[2] Brummett B. H., Krystal A. D., Siegler I. C., Kuhn C., Surwit R. S., Züchner S., … Williams R. B. (2007). Associations of a regulatory polymorphism of monoamine oxidase-A gene promoter (MAOA-uVNTR) with symptoms of depression and sleep quality.Psychosom Med, 69(5), 396-401. doi: 10.1097/psy.0b013e31806d040b
[3] Bryant R. A., Felmingham K. L., Falconer E. M., Pe Benito L., Dobson-Stone C., Pierce K. D.,.. Schofield P. R. (2010). Preliminary evidence of the short allele of the serotonin trans-porter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder.Biol Psychiatry, 67(12), 1217-1219. doi: 10.1016/j.biopsych.2010.03.016
[4] Caspi A., Hariri A. R., Holmes A., Uher R., & Moffitt T. E. (2010). Genetic sensitivity to the environment: The case of the serotonin transporter gene and its implications for studying complex diseases and traits.Am J Psychiatry, 167(5), 509-527. doi: 10.1176/appi.ajp.2010.09101452
[5] Caspi A., Sugden K., Moffitt T. E., Taylor A., Craig I. W., Harrington H.,.. Poulton R. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene.Science, 301(5631), 386-389. doi: 10.1126/science.1083968
[6] Dorado P., Peñas-Lledó E. M., González A. P., Cáceres M. C., Cobaleda J., & Llerena A. (2007). Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele.Fundam Clin Pharmacol, 21(4), 451-453. doi: 10.1111/j.1472-8206.2007.00501.x
[7] Eley T. C., Hudson J. L., Creswell C., Tropeano M., Lester K. J., Cooper P.,.. Collier D. A. (2012). Therapygenetics: the 5HTTLPR and response to psychological therapy.Mol Psychiatry, 17(3), 236-237. doi: 10.1038/mp.2011.132
[8] Fan M., Liu B., Jiang T., Jiang X., Zhao H., & Zhang J. (2010). Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders.Psychiatr Genet, 20(1), 1-7. doi: 10.1097/YPG.0b013e3283351112
[9] Fox E., Zougkou K., Ridgewell A., & Garner K. (2011). The serotonin transporter gene alters sensitivity to attention bias modification: Evidence for a plasticity gene.Biol Psychiatry, 70(11), 1049-1054. doi: 10.1016/j.biopsych.2011.07.004
[10] Gottschalk M. G., Richter J., Ziegler C., Schiele M. A., Mann J., Geiger M. J.,.. Domschke K. (2019). Orexin in the anxiety spectrum: Association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes.Transl Psychiatry, 9(1), 75. doi: 10.1038/s41398-019-0415-8
[11] Hariri A. R., Drabant E. M., Munoz K. E., Kolachana B. S., Mattay V. S., Egan M. F.,.. & Weinberger, D. R. (2005). A susceptibility gene for affective disorders and the response of the human amygdala.Arch Gen Psychiatry, 62(2), 146. doi: 10.1001/arch psyc.62.2.146
[12] Hariri A. R., Mattay V. S., Tessitore A., Kolachana B., Fera F., Goldman D.,.. Weinberger D. R. (2002). Serotonin transporter genetic variation and the response of the human amygdala.Science, 297(5580), 400-403. doi: 10.1126/science.1071829
[13] Ijaz S., Davies P., Williams C. J., Kessler D., Lewis G., Wiles N. (2018). Psychological therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev, 5(5), CD010558. doi: 10.1002/14651858.CD010558.pub2
[14] Karg K., Burmeister M., Shedden K., & Sen S. (2011). The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited.Arch Gen Psychiatry, 68(5), 444. doi: 10.1001/archgenpsychiatry.2010.189
[15] Koh K. B., Choi E. H., Lee Y. J., Han M., Choi S. S., Kim S. W.,.. Lee M. G. (2012). The relation of serotonin-related gene and COMT gene polymorphisms with criminal behavior in schizophrenic disorder.J Clin Psychiatry, 73(2), 159-163. doi: 10.4088/jcp.10m06443
[16] Laws, K. R., Darlington, N., Kondel, T. K., McKenna, P. J., & Jauhar, S. (2018). Cognitive Behavioural Therapy for schizophrenia-outcomes for functioning, distress and quality of life: A meta-analysis. BMC Psychology, 6(1), 1-10. doi: 10.1186/s40359-018-0243-2Llerena, A., Berecz, R., Dorado, P., González, A. P., Peñas-Lledó, E. M., de la Rubia, A. (2003). CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenomics J, 3(5), 300-302. doi: 10.1038/sj.tpj.6500197
[17] Lester, K. J., & Eley, T. C. (2013). Therapygenetics: Using genetic markers to predict response to psychological treatment for mood and anxiety disorders.Biol Mood Anxiety Disord, 3(1), 4. doi: 10.1186/2045-5380-3-4
[18] Lester K. J., Hudson J. L., Tropeano M., Creswell C., Collier D. A., Farmer A.,.. Eley T. C. (2012). Neurotrophic gene polymorphisms and response to psychological therapy.Transl Psychiatry, 2(5), e108. doi: 10.1038/tp.2012.33
[19] Levitt H. M., Pomerville A., Surace F. I., & Grabowski L. M. (2017). Metamethod study of qualitative psychotherapy research on clients’ experiences: Review and recommendations. J Couns Psychol, 64(6), 626-644. doi: 10.1037/cou0000222
[20] Lonsdorf, T. B., & Kalisch, R. (2011). A review on experimental and clinical genetic associations studies on fear conditioning, extinction and cognitive-behavioral treatment.Transl Psychiatry, 1(9), e41. doi: 10.1038/tp.2011.36
[21] Lonsdorf T. B., Rück C., Bergström J., Andersson G., Öhman A., Lindefors N.,.. Schalling M. (2010). The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder.BMC Psychiatry, 10(1), 1-9. doi: 10.1186/1471-244X-10-99
[22] Lueken U., Straube B., Wittchen H. U., Konrad C., Ströhle A., Wittmann A.,.. Reif A. (2015). Therapygenetics: anterior cingulate cortex-amygdala coupling is associated with 5-HTTLPR and treatment response in panic disorder with agoraphobia. J Neural Transm, 122(1), 135-144. doi: 10.1007/s00702-014-1311-2
[23] Lung F. W., Tzeng D. S., Huang M. F., & Lee M. B. (2011). Association of the MAOA promoter uVNTR polymorphism with suicide attempts in patients with major depressive disorder.BMC Med Genet, 12, 74. doi: 10.1186/1471-2350-12-74
[24] Pariante, C. M., & Lightman, S. L. (2008). The HPA axis in major depression: Classical theories and new developments.Trends Neurosci, 31(9), 464-468. doi: 10.1016/j.tins.2008.06.006
[25] Pérez V., Pascual J. C., Soler J., Tiana T., Cortés A., Baiget M.,.. Álvarez, E.(2010). Psychotherapygenetic: do genes influence psychotherapy adherence?Revista De Psiquiatría y Salud Mental (English Edition), 3(2), 68-71. doi: 10.1016/S2173-5050(10)70012-1
[26] Perroud, N., Salzmann, A., Prada, P., Nicastro, R., Hoeppli, M. E., Furrer, S.,... Malafosse, A. (2013). Response to psychotherapy in borderline personality disorder and methylation status of the BDNF gene. Transl Psychiatry, 3(1), e207. doi: 10.1038/tp.2012.140
[27] Reif A., Richter J., Straube B., Höfler M., Lueken U., Gloster A. T.,.. Deckert J. (2014). MAOA and mechanisms of panic disorder revisited: From bench to molecular psychotherapy.Mol Psychiatry, 19(1), 122-128. doi: 10.1038/mp.2012.172
[28] Schiele M. A., Thiel C., Deckert J., Zaudig M., Berberich G., & Domschke K. (2020). Monoamine oxidase A hypomethylation in obsessive-compulsive disorder: Reversibility by successful psychotherapy?Int J Neuropsychopharmacol, 23(5), 319-323. doi: 10.1093/ijnp/pyaa016
[29] Schiele M. A., Ziegler C., Kollert L., Katzorke A., Schartner C., Busch Y.,.. Domschke K. (2018). Plasticity of functional MAOA gene methylation in acrophobia.Int J Neuropsychopharmacol, 21(9), 822-827. doi: 10.1093/ijnp/pyy050
[30] Schulze, T. G., Müller, D. J., Krauss, H., Scherk, H., Ohlraun, S., Syagailo, Y. V.,... Rietschel, M. (2000). Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet, 96(6), 801-803. doi: 10.1002/1096-8628(20001204)96: 6801: AID-AJMG21>3.0.CO;2-4
[31] Shen H., Chen M. J., & Cui D. H. (2020). Biological mechanism study of meditation and its application in mental disorders.General Psychiatry, 33(4), e100214. doi: 10.1136/gpsych-2020-100214
[32] Trautmann S., Richter J., Muehlhan M., Höfler M., Wittchen H. U., Domschke K.,.. Reif A. (2019). Does prior traumatization affect the treatment outcome of CBT for panic disorder? The potential role of the MAOA gene and depression symptoms.Eur Arch Psychiatry Clin Neurosci, 269(2), 161-170. doi: 10.1007/s00406-017-0823-9
[33] Ziegler C., Grundner-Culemann F., Schiele M. A., Schlosser P., Kollert L., Mahr M.,.. Domschke K. (2019). The DNA methylome in panic disorder: A case-control and longitudinal psychotherapy-epigenetic study.Transl Psychiatry, 9, 314. doi: 10.1038/s41398-019-0648-6
[34] Ziegler C., Richter J., Mahr M., Gajewska A., Schiele M. A., Gehrmann A.,.. Domschke K. (2016). MAOA gene hypomethylation in panic disorder-reversibility of an epigenetic risk pattern by psychotherapy.Transl Psychiatry, 6(4), e773. doi: 10.1038/tp.2016.41
